
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.
Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 12, 8, 1, 51, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.
Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 12, 8, 1, 51, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
176 Pages
- Introduction
- Global Markets Direct Report Coverage
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Overview
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Companies Involved in Therapeutics Development
- 9 Meters Biopharma Inc
- Advanced Innovative Partners Inc
- Advenchen Laboratories LLC
- Aileron Therapeutics Inc
- Allander Biotechnologies LLC
- Amryt Pharma Plc
- Aqualung Therapeutics Corp
- BCN Biosciences LLC
- BioCurity Pharmaceuticals Inc
- BioIncept LLC
- Bolder Biotechnology Inc
- Cellphire Inc
- Ceramedix Holding LLC
- Ceramide Therapeutics LLC
- Chrysalis BioTherapeutics Inc
- Clevexel Pharma SA
- Connext Co Ltd
- Consegna Pharma Inc
- Creative Medical Technology Holdings Inc
- Devonian Health Group Inc
- Enveric Biosciences Inc
- Enzychem Lifesciences Corp
- EpicentRx Inc
- Exponential Biotherapies Inc
- Extend Biosciences Inc
- Fibroplate Inc
- Foresee Pharmaceuticals Co Ltd
- Genexine Inc
- Genome Protection Inc
- GNI Group Ltd
- Humanetics Corp
- iNtRON Biotechnology Inc
- KBP Biosciences Co Ltd
- Lutris Pharma
- Luxena Pharmaceuticals Inc
- Matrix Biomed Inc
- Meabco AS
- Medesis Pharma SA
- Neumedicines Inc
- Neuropathix Inc
- New Amsterdam Sciences Inc
- Novartis AG
- Noveome Biotherapeutics Inc
- Onconova Therapeutics Inc
- Original BioMedicals Co Ltd
- Oxacell AG
- P2D Inc
- Partner Therapeutics Inc
- Perpetuum BV
- PharmaIN Corp
- Phoenicia Biosciences Inc
- Pluristem Therapeutics Inc
- Regeneus Ltd
- RepoCeuticals ApS
- RxBio Inc
- Soligenix Inc
- Statera Biopharma Inc
- Sunny Pharmtech Inc
- Synedgen Inc
- TheraSource LLC
- Tonix Pharmaceuticals Holding Corp
- Valenta Pharm
- VasoDynamics Ltd
- Vera Salus Ricerca Srl
- Worphmed Srl
- Xequel Bio Inc
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drug Profiles
- A-02 – Drug Profile
- aCT11 – Drug Profile
- ALT-200 – Drug Profile
- AmnioStem – Drug Profile
- Antibody for Acute Radiation Gastrointestinal Syndrome – Drug Profile
- apatinib mesylate – Drug Profile
- avoplacel – Drug Profile
- BBT-007 – Drug Profile
- BBT-015 – Drug Profile
- BBT-059 – Drug Profile
- BCN-057 – Drug Profile
- BIO-301 – Drug Profile
- Biologic for Radiodermatitis – Drug Profile
- birch triterpenes – Drug Profile
- BPC-2 – Drug Profile
- Ca-DTPA – Drug Profile
- cannabidiol – Drug Profile
- cerium oxide – Drug Profile
- CP-215 – Drug Profile
- CVXL-0095 – Drug Profile
- Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And Oncology – Drug Profile
- EA-230 – Drug Profile
- efineptakin alfa – Drug Profile
- eltrombopag olamine – Drug Profile
- enamptcumab – Drug Profile
- entolimod – Drug Profile
- EWA-001 – Drug Profile
- EXT-405 – Drug Profile
- Fibrinoplate-S – Drug Profile
- FP-045 – Drug Profile
- Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity – Drug Profile
- genistein – Drug Profile
- GP-532 – Drug Profile
- Granexin – Drug Profile
- imidazolyl ethanamide pentandioic acid – Drug Profile
- Indralin – Drug Profile
- JP-4039 – Drug Profile
- KBP-8017 – Drug Profile
- KLS-13019 – Drug Profile
- KMRC-011 – Drug Profile
- LPI-1504 – Drug Profile
- LPI-1505 – Drug Profile
- LUT-014 – Drug Profile
- m-2A2 – Drug Profile
- melatonin – Drug Profile
- MIIST-305 – Drug Profile
- mosedipimod – Drug Profile
- NAS-150 – Drug Profile
- NAS-911 – Drug Profile
- NG-121 – Drug Profile
- NG-122 – Drug Profile
- NMIL-121 – Drug Profile
- NP-02 – Drug Profile
- ondansetron – Drug Profile
- PCSMD-05 – Drug Profile
- Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis – Drug Profile
- phenylbutyrate – Drug Profile
- pirfenidone – Drug Profile
- Preimplantation Factor – Drug Profile
- PUR-0110 – Drug Profile
- RDD-2007 – Drug Profile
- recilisib sodium – Drug Profile
- Recombinant Peptides for Radiation Injury – Drug Profile
- Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity – Drug Profile
- Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis – Drug Profile
- Recombinant Protein to Activate FGF-4 for Radiation Injury – Drug Profile
- Recombinant Protein to Activate FGF-7 for Radiation Injury – Drug Profile
- RP-239X – Drug Profile
- RRX-001 – Drug Profile
- rusalatide acetate – Drug Profile
- Rx-100 – Drug Profile
- sargramostim – Drug Profile
- SGX-201 – Drug Profile
- SGX-202 – Drug Profile
- Small Molecule for Prostate Cancer and Radiation Injury – Drug Profile
- Small Molecule to Chelate Gadolinium for Radiation Toxicity – Drug Profile
- Small Molecules for Chemotherapy Effects and Radiation Toxicity – Drug Profile
- Small Molecules to Inhibit NO Synthase for Osteoporosis, Radiation Toxicity and Wounds – Drug Profile
- ST-266 – Drug Profile
- ST-7 – Drug Profile
- Stem Cell Therapy for Skin Disorders – Drug Profile
- sulanemadlin – Drug Profile
- SY-513 – Drug Profile
- Sygenus – Drug Profile
- SYGN-399 – Drug Profile
- Tempol – Drug Profile
- Thrombosomes – Drug Profile
- TNX-701 – Drug Profile
- ZM-241385 – Drug Profile
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Product Development Milestones
- Featured News & Press Releases
- Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the Radiation Research Society 2022 annual meeting
- Jul 21, 2022: Eckert & Ziegler Affiliate receives further NIAID funding for clinical development
- Apr 26, 2022: New studies published comparing BIO 300 to Neulasta for acute radiation syndrome
- Mar 24, 2022: Tanner Pharma increases Europe-based inventory of Leukine to expand availability and enhance response to potential radiation exposure due to the ongoing Conflict in Ukraine
- Dec 01, 2021: Statera Biopharma announces FDA lifts clinical hold on entolimod
- Nov 18, 2021: Enveric Biosciences announces positive preclinical data for EV102 Radiodermatitis Drug Candidate
- Sep 22, 2021: Humanetics announces results from phase 1 trial of BIO 300 oral powder
- Jul 20, 2021: Neuropathix announces publication of PCT patent application for the treatment of radiation dermatitis and other skin disorders
- Jun 08, 2021: Affiliate receives additional NIAID funding to advance pharmaceutical development
- Feb 18, 2021: Partner Therapeutics announces publication of two studies demonstrating Leukine improves survival in Acute Radiation Syndrome (ARS)
- Feb 08, 2021: Enzychem Lifesciences announces poster presentation at AACR Virtual Annual Meeting 2021
- Jan 26, 2021: Enzychem Lifesciences receives NASA grant funding to evaluate EC-18 as a protective agent for radiation and pathogen-induced tissue damage and inflammation in space
- Oct 20, 2020: Humanetics presents at the Annual Radiation Research Society meeting
- Oct 15, 2020: Meabco's drug candidate efficiently mitigates radiation-induced gastrointestinal syndrome in mice
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Companies, 2022 (Contd..4)
- Table 11: Products under Development by Universities/Institutes, 2022
- Table 12: Number of Products by Stage and Target, 2022
- Table 13: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 16: Number of Products by Stage and Route of Administration, 2022
- Table 17: Number of Products by Stage and Molecule Type, 2022
- Table 18: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by 9 Meters Biopharma Inc, 2022
- Table 19: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Advanced Innovative Partners Inc, 2022
- Table 20: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Advenchen Laboratories LLC, 2022
- Table 21: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Aileron Therapeutics Inc, 2022
- Table 22: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Allander Biotechnologies LLC, 2022
- Table 23: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Amryt Pharma Plc, 2022
- Table 24: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Aqualung Therapeutics Corp, 2022
- Table 25: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by BCN Biosciences LLC, 2022
- Table 26: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by BioCurity Pharmaceuticals Inc, 2022
- Table 27: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by BioIncept LLC, 2022
- Table 28: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Bolder Biotechnology Inc, 2022
- Table 29: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cellphire Inc, 2022
- Table 30: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Ceramedix Holding LLC, 2022
- Table 31: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Ceramide Therapeutics LLC, 2022
- Table 32: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Chrysalis BioTherapeutics Inc, 2022
- Table 33: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Clevexel Pharma SA, 2022
- Table 34: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Connext Co Ltd, 2022
- Table 35: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Consegna Pharma Inc, 2022
- Table 36: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Creative Medical Technology Holdings Inc, 2022
- Table 37: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Devonian Health Group Inc, 2022
- Table 38: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Enveric Biosciences Inc, 2022
- Table 39: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Enzychem Lifesciences Corp, 2022
- Table 40: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by EpicentRx Inc, 2022
- Table 41: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Exponential Biotherapies Inc, 2022
- Table 42: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Extend Biosciences Inc, 2022
- Table 43: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Fibroplate Inc, 2022
- Table 44: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
- Table 45: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Genexine Inc, 2022
- Table 46: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Genome Protection Inc, 2022
- Table 47: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by GNI Group Ltd, 2022
- Table 48: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Humanetics Corp, 2022
- Table 49: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by iNtRON Biotechnology Inc, 2022
- Table 50: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by KBP Biosciences Co Ltd, 2022
- Table 51: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Lutris Pharma, 2022
- Table 52: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Luxena Pharmaceuticals Inc, 2022
- Table 53: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Matrix Biomed Inc, 2022
- Table 54: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Meabco AS, 2022
- Table 55: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Medesis Pharma SA, 2022
- Table 56: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Neumedicines Inc, 2022
- Table 57: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Neuropathix Inc, 2022
- Table 58: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by New Amsterdam Sciences Inc, 2022
- Table 59: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Novartis AG, 2022
- Table 60: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Noveome Biotherapeutics Inc, 2022
- Table 61: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Onconova Therapeutics Inc, 2022
- Table 62: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Original BioMedicals Co Ltd, 2022
- Table 63: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Oxacell AG, 2022
- Table 64: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by P2D Inc, 2022
- Table 65: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Partner Therapeutics Inc, 2022
- Table 66: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Perpetuum BV, 2022
- Table 67: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by PharmaIN Corp, 2022
- Table 68: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Phoenicia Biosciences Inc, 2022
- Table 69: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Pluristem Therapeutics Inc, 2022
- Table 70: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Regeneus Ltd, 2022
- Table 71: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RepoCeuticals ApS, 2022
- Table 72: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RxBio Inc, 2022
- Table 73: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Soligenix Inc, 2022
- Table 74: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Statera Biopharma Inc, 2022
- Table 75: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Sunny Pharmtech Inc, 2022
- Table 76: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Synedgen Inc, 2022
- Table 77: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by TheraSource LLC, 2022
- Table 78: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
- Table 79: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Valenta Pharm, 2022
- Table 80: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by VasoDynamics Ltd, 2022
- Table 81: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Vera Salus Ricerca Srl, 2022
- Table 82: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Worphmed Srl, 2022
- Table 83: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Xequel Bio Inc, 2022
- Table 84: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, 2022
- Table 85: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, 2022 (Contd..1)
- Table 86: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, 2022 (Contd..2)
- Table 87: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, 2022 (Contd..3)
- Table 88: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, 2022 (Contd..4)
- Table 89: Table 90: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.